Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study-Reference-Cited by-同舟云学术

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

Published:2024-01-30 Issue:3 Volume:41 Page:1184-1200
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Lehrke Michael^ORCID,Vogt Anja,Schettler Volker^ORCID,Girndt Matthias^ORCID,Fraass Uwe^ORCID,Tabbert-Zitzler Anja,Bridges Ian^ORCID,Dhalwani Nafeesa N.^ORCID,Ray Kausik K.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02757-x.pdf

Reference24 articles.

1. World Health Organisation. Cardiovascular diseases (CVDs). 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 23 June 2022.

2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.

3. Statistisches Bundesamt Deutschland. Todesursachen in Deutschland. 2022. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-herz-kreislauf-erkrankungen-insgesamt.html. Accessed 20 Mar 2023.

4. Gesundheitsberichterstattung des Bundes. Sterbefälle (absolut, Sterbeziffer, Ränge, Anteile) für die 10/20/50/100 häufigsten Todesursachen (ab 1998). Gliederungsmerkmale: Jahre, Region, Alter, Geschlecht, ICD-10. 2023. https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gastd&p_aid=79977881&p_sprache=D&p_help=0&p_indnr=516&p_indsp=4065&p_ityp=H&p_fid=. Accessed 20 Mar 2023.

5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.